Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
The reported $500 million agreement covers 371 episodes and expands access beyond the United States beginning in 2027.
The $80 million to $90 million arrangement moves more than 20 employees without a formal company purchase.